Advertisement
Advertisement

TARS

TARS logo

Tarsus Pharmaceuticals Inc

53.30
USD
+1.57
+3.04%
Dec 17, 15:59 UTC -5
Closed
...

Tarsus Pharmaceuticals Inc Profile

About

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif.

Info & Links

CEO

Bobak Azamian

Headquarters

15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE, CA 92618, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

32

Employees

244

Tarsus Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

2.04B

Enterprise Value

1.93B

Enterprise Value/EBITDA(ttm)

-13.63

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

15.48

Price to Book(mrq)

8.41

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

92.65%

Operating Margin(ttm)

-103.64%

Profit Margin(ttm)

-145.02%

Return on Equity(ttm)

-55.86%

Return on Invested Capital(ttm)

-48.04%

Return on Assets(ttm)

-39.28%

Income Statement

Revenue(ttm)

129.62M

Revenue Per Share(ttm)

3.39

Gross Profit(ttm)

120.51M

EBITDA(ttm)3

-141.86M

Net Income Available to Common(ttm)

-134.34M

Diluted EPS(ttm)

-3.81

Share Statistics

Beta (5Y Monthly)

1.04

52-Week Change

224.60%

S&P 500 52-Week Change

27.63%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

38.23M

Dividend Yield

0.00%

Float4

35.07M

% Held by Insiders

8.25%

% Held by Institutions

90.01%

Balance Sheet

Total Cash(mrq)

316.95M

Total Cash Per Share(mrq)

8.29

Total Debt(mrq)

71.71M

Total Debt/Equity(mrq)

30.19%

Current Ratio(mrq)

5.42%

Quick Ratio(mrq)

5.38%

Book Value Per Share(mrq)

6.22

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.59

Free Cash Flow(ytd)

-62.34M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement